Celator Announces Phase 3 Trial for VYXEOS™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival
March 14, 2016First therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a pivotal Phase 3 trial in high-risk AML.
More »
Landmark Study Published in American Journal of Obstetrics & Gynecology Validates New Blood Test as Objective, Predictive Tool for Preterm Birth Risk
March 10, 2016The PreTRM® Test is Now Commercially Available to Predict Risk Early in Pregnancy
More »
Aldeyra Therapeutics Reports Positive Results from Phase IIa Clinical Trial in Subjects with Allergic Conjunctivitis
February 29, 2016NS2 Demonstrates Statistically Significant and Sustained Clinical Effects
More »